Pelthos Therapeutics secured a $50 million senior secured term loan facility from Horizon Technology Finance to accelerate commercialization efforts for its lead product, ZELSUVMI™.
The funding will also support the commercialization of two newly acquired FDA approved cutaneous infectious disease products and general corporate purposes.
The financing includes an initial $30 million with an additional $20 million available for future growth and is considered minimally dilutive to existing shareholders.
Funding Purpose
The funding aims to accelerate commercialization efforts for ZELSUVMI™ and other FDA approved products, along with supporting working capital needs.
Non-Dilutive Financing
The capital raised through the loan facility is non-dilutive to existing shareholders of Pelthos.
Support from Horizon
Horizon Technology Finance Corporation funded $30 million initially with an additional $20 million available upon meeting certain milestones.
- The funding provides Pelthos with the flexibility and resources to advance the commercialization of its innovative products, addressing significant unmet needs in the dermatologic field.
- The partnership with Horizon strengthens Pelthos' balance sheet and allows for the continued development and expansion of treatment options for patients in need.
The secured term loan facility from Horizon Technology Finance marks a significant milestone for Pelthos Therapeutics, enabling the company to further its mission of providing innovative treatment options for patients with cutaneous infections.